1. OzierY, Steibt A, Ickx B et al. (2001). Hemostatic disorders during liver transplantation. EurJAnaesthesiol 18: 208-218.

2. Mahmoud, AEA, Elias E, Beauchamp N, Wilde JT. (1997). Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 40(6): 798-800.

3. Ben-Ari Z, Panagou M, Patch D et al. (1997). Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J Hepatol 26(3): 554-559.

4. FungJ, Marcos A. (2003). Rapamycin: friend, foe or misunderstood? Liver Transpl 9(5): 469-472.

5. Whitten CW, Greilich PE. (2000). Thromboelastography: past, present, and future. Anesthesiology 92(5): 1226-1228.

6. Planinsic RM, Nicolau-Raducu R, Caldwell JC, Aggarwal S, Hilmi I. (2003). Transesophageal echocardiography-guided placement of internal jugular percutaneous venovenous bypass cannula in orthotopic liver transplantation. Anesth Analg 97: 648--649.

7. Kang Y, Lewis JH, Navalgund A et al. (1987). Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 66: 766--773.

8. Mannucci, PM. (2001). Drug therapy: hemostatic drugs. The New Engl J Med 339(4): 245-253.

9. MolenaarlQ, Legnani C, Groenland THN etal. (2001). Aprotinin in orthotopic liver transplantation: evidence for a prohemostatic, but not a prothrombotic effect. Liver Transpl 7: 896-903.

10. Boylan J, Klinck F, Sandler JR, Alan N et al. (1996). Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 85(5): 1043-1048.

11. Kettner SC, Gonano C, Seebach F et al. (1998). Endogenous heparin-like substances significantly impair coagulation in patients undergoing orthotopic liver transplantation. Anesth Analg 86(4): 691-695.

12. Soilleux H, Gillon MC, Mirand A et al. (1995). Comparative effect of small and large aprotinin doses on bleeding during orthotopic liver transplantation. Anesth Analg 80(2): 349-352.

13. Marcel R, Stegall W, Suit CT et al. (1996). Continuous small-dose aprotinin controls fibrinolysis during orthotopic liver transplantation. Anesth Analg 82(6): 1122-1125.

14. Porte RJ, Molenaar IQ, Begliomini B et al. (2000). Aprotinin and transfusion requirement in orthotopic liver transplantation: a multicentre randomised double-blind study. Lancet 355(9212): 1303-1309.

15. De Hert SG, Farooqi NU, Delrue GL et al. (1996). Dose dependent effect of aprotinin on rate of clot formation. Eur J Anaesthesiol 13(5): 463-467.

16. Planinsic RM, Testa G, Emre S et al. (2001). Use of recombinant factor Vila in patients undergoing orthotopic liver transplantation. The 6th NovoSeven Copenhagen symposium on the treatment of bleeding disorders and thrombotic disorders abstract publication.

17. Planinsic RM, Milroy SJ, Hilmi IA et al. (2001). Use of recombinant factor VIIa may improve clotting parameters in patients undergoing orthotopic liver transplantation (OLT) as measured by thromboelastography (TEG). Liver Transpl Surg 7(6): C-18 (72).

18. Kohler M. (1998). Antithrombin (AT) substitution: sense or nonsense? Anaesthesia 53(Suppl 2): 52-54.

19. Gologorsky E, De Wolf AM, Scott V et al. (2001). Intracardiac thrombus formation and pulmonary thromboembolism immediately after graft reperfusion in 7 patients undergoing liver transplantation. Liver Transpl 7(9): 783-789.

20. Fitzsimons MG, Peterfreund RA, Raines DE. (2001). Aprotinin administration and pulmonary thromboembolism during orthotopic liver transplantation: report of two cases. Anesth Analg 92: 1418-1421.

21. O'Connor CJ, Roozeboom D, Brown R, Tuman KJ (2000). Pulmonary throm-boembolism during liver transplantation: possible association with antifibri-nolytic drug and novel treatment options. Anesth Analg 91(2): 296-299.

22. Sopher M, Braunfeld M, Shackleton C et al. (1997). Fatal pulmonary embolism during liver transplantation. Anesthesiology 87(2): 429-432.

23. Planinsic RM, Nicolau-Raducu R, Eghtesad B, Marcos A. (2004). Diagnosis and treatment of intracardiac thrombosis during orthotopic liver transplantation. Anesth Analg 99(2): 353-356.

24. Tai NRM, Atwal AS, Hamilton G. (1999). Modern management of pulmonary embolism. Br J Surg 86(7): 853-868.

25. Kettner SC, Gonano C, Seebach F et al. (1998). Endogenous heparin-like substances significantly impair coagulation in patients undergoing orthotopic liver transplantation. Anesth Analg 86(4): 691-695.

26. DeWolf AM, Ramsey G, Teruya J et al. (2003). Hypercoagulability and pulmonary thromboembolism during liver transplantation: what is the role of heparin administration? Liver Transpl Surg 9(6): C-40 (157).

27. Kohler M. (1998). Antithrombin (AT III) substitution: sense or nonsense? Thromboembolic complication and coagulation monitoring. Anesthesia 53(2): 52-54.

28. Haynes G, LazarchickJ, Palesch Y et al. (1998). Antithrombin III activity associated with disseminated intravascular coagulation in orthotopic liver transplantation. Anesthesiology 89(3AS): 412A.

29. Linde T, Sandhagen B, Backman U, Fellstrom B. (1999). Altered flow properties of blood and increased plasma fibrinogen in cyclosporin-treated renal allograft recipients. Nephrol Dial Transplant 14: 1525-1529.

30. Sartori TM, Maurizio PG, Sara P, Ugolino L, Annalisa A, Panagiotis T, Massimo F, Antonio G. (1999). Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation. J Heart Lung Transplant 18: 693-700.

31. McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. (2000). Sirolimus-tacrolimus combination immunosuppression. Lancet 355: 376-377.

32. McAlister VC, Peltekian KM, Malatjalian DA, Colohan S, MacDonald S, Bitter-Suermann H, MacDonald AS. (2001). Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 7: 701-708.

33. Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T, Everson GT, Kam I. (2003). Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 9(5): 463-468.

34. Ankersmit HJ, Roth GA, Moser B, Zuckermann A, Brunner M, Rosin C, Buchta C, Bielek E, Schmid W, Jensen-Jarolim E, Wolner E, Boltz-Nitulescu G, Volf I. (2003). CD32-mediated platelet aggregation in vitro by anti-thymocyte globulin: implication of therapy-induced in vivo thrombocytopenia. Am JTranspl 3(6): 754-759.

35. FramptonJE, Wagstaff AJ. (2003). Alemtuzumab. Drugs 63(12): 1229-1243.

Was this article helpful?

0 0

Post a comment